Department of International Health, School of Nursing and Health Studies, Georgetown University, Washington, DC, USA.
Shanghai Jiao Tong University School of Medicine, Shanghai, China; China Hospital Management Institute, Shanghai Jiao Tong University, Shanghai, China.
Vaccine. 2021 Oct 15;39(43):6356-6363. doi: 10.1016/j.vaccine.2021.09.044. Epub 2021 Sep 25.
This study is to examine the cost-effectiveness of deployment strategies of oral cholera vaccines (OCVs) in controlling cholera in Bangladesh. We developed a dynamic compartment model to simulate costs and health outcomes for 12 years for four OCVs deployment scenarios: (1) vaccination of children aged one and above with two doses of OCVs, (2) vaccination of population aged 5 and above with a single dose of OCVs, (3) vaccination of children aged 1-4 with two doses of OCVs; and (4) combined strategy of (2) and (3). We obtained all parameters from the literature and performed a cost-effectiveness analysis from both health systems and societal perspectives, in comparison with the base scenario of no vaccination.The incremental cost-effectiveness ratios (ICERs) for the four strategies from the societal perspective were $2,236, $2,250, $1,109, and $2,112 per DALY averted, respectively, with herd immunity being considered. Without herd immunity, the ICERs increased substantially for all four scenarios except for the scenario that vaccinates children aged 1-4 only. The major determinants of ICERs were the case fatality rate and the incidence of cholera, as well as the efficacy of OCVs. The projection period and frequency of administering OCVs would also affect the cost-effectiveness of OCVs. With the cut-off of 1.5 times gross domestic product per capita, the four OCVs deployment strategies are cost-effective. The combined strategy is more efficient than the strategy of vaccinating the population aged one and above with two doses of OCVs and could be considered in the resource-limited settings.
本研究旨在考察在孟加拉国控制霍乱的口服霍乱疫苗(OCV)部署策略的成本效益。我们开发了一个动态房室模型,模拟了四种 OCV 部署方案在 12 年内的成本和健康结果:(1)为 1 岁及以上的儿童接种两剂 OCV;(2)为 5 岁及以上的人群接种一剂 OCV;(3)为 1-4 岁的儿童接种两剂 OCV;(4)(2)和(3)的联合策略。我们从文献中获取了所有参数,并从卫生系统和社会两个角度进行了成本效益分析,与不接种疫苗的基础方案进行了比较。从社会角度来看,四种策略的增量成本效益比(ICER)分别为每例 DALY 避免 2236 美元、2250 美元、1109 美元和 2112 美元,同时考虑了群体免疫。如果不考虑群体免疫,除了只给 1-4 岁儿童接种疫苗的方案外,所有四个方案的 ICER 都会大幅增加。ICER 的主要决定因素是病死率和霍乱发病率,以及 OCV 的效力。OCV 的接种期限和接种频率也会影响 OCV 的成本效益。以人均国内生产总值的 1.5 倍为临界点,四种 OCV 部署策略都是具有成本效益的。联合策略比为 1 岁及以上人群接种两剂 OCV 的策略更有效率,可在资源有限的情况下考虑。